Clinical Trial Update: Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for an immune program of a recombinant COVID-19 vaccine (CHO cell) by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., with sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• recombinant coronavirus vaccine (CHO cell) for COVID-19

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Coronavirus Disease 2019 | Phase 3 | Status: UNKNOWN